


بسم الله الرحمن الرحيم





شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات




يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار






بعض الوثائق الأصلية تالفة





بالرسالة صفحات
لم ترد بالأصل





Faculty of Pharmacy

Pharmaceutical Chemistry Dept.

Radiostability and Antibacterial Activity of some New Halogenated 1,3-Thiazolidin-4- one Derivatives

A Thesis

Submitted in Partial Fulfillment of the Requirements for the

Master degree

In Pharmaceutical Sciences

(Pharmaceutical Chemistry)

By

Shaymaa Gamal Hammad El-Sayed

Pharmacist in Egyptian Atomic Energy Authority

Bachelor Degree in Pharmaceutical Sciences

Faculty of Pharmacy, Ain Shams University, 2014

Under Supervision of

Dr. Khaled Abouzid Mohamed, PhD

Professor of Pharmaceutical Chemistry,

Faculty of Pharmacy, Ain Shams University,

Dean of Faculty of pharmacy, University of Sadat City

Dr. Marwa Galal El-Din El-Gazzar, PhD

Associate Professor of Pharmaceutical Chemistry,

Egyptian Atomic Energy Authority

Dr. Eman Zaghlol El-Razaz, PhD

Lecturer of Pharmaceutical Chemistry,

Faculty of Pharmacy, Ain-Shams University

2020

Acknowledgments

Firstly, I would like to start with thanking "**Allah**" for granting me the power and patience to accomplish this work and to master it as best as I could despite all the present challenges (Alhamdulillah).

I wish foremost to express my deepest and unlimited thanks to **Prof Dr Khaled Abouzeid Mohamed**, Professor of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University and Dean of Faculty of Pharmacy El-Sadat University, for his valuable scientific supervision, constructive advice and continuous guidance throughout the work. No words can express the extent of his assistance and advice to me. I sincerely appreciate his approach in dealing with his students and in being multi-tasking, he is available all the time for anyone who needs or asks him. He is really my teacher in this field.

My deepest appreciation is expressed to **Assoc Prof Dr Marwa Galal El-Gazzar**, Assoc Prof of Pharmaceutical Chemistry, National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA), for her continuous support and guiding me to the right path to achieve my work. Her efforts played a great role in finishing our work in this form. She was and still is with me, step by step.

I am deeply grateful to **Dr Eman Zaghalol**, Lecturer of Pharmaceutical Chemistry, Ain Shams University, for her valuable assistance and constant encouragement, especially during writing this thesis.

I am also greatly indebted to **Dr Ebaa El-Hossary**, Lecturer of Pharmaceutical Chemistry, National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA), for his continuous support and suggestions throughout the whole work.

I want to thank **Assoc Prof Dr Mohammed Abdel-Haliem**, Assoc Prof of Pharmaceutical Chemistry, Germany University in Cairo, for performing LC-MS and HPLC purity analysis and advice during the practical work and writing.

Words couldn't express nor describe my special thanks for all the following **Prof Dr Mohamed Seleem**, Prof of Microbiology, Purdue University, West Lafayette, and his two students, **Nader Abutaleb** and **Daoyi Li**, as well as **Prof Dr Ursula Bilitewski**, Prof of Biochemistry, Helmholtz Center for Infection Research, and her two students, **Aditya Shekhar** and **Isabell Ramming**, for their help in performing the biological investigations.

I acknowledge with my deep thankfulness **all my dear colleagues in the Drug Chemistry Lab** in NCRRT and to **all workers** and **staff members** in it who gave me any help or support for the fulfillment of this work.

Finally, I need to express my grateful thanks to the administration of **National Center for Radiation Research and Technology** (NCRRT), for providing all the facilities and supplies throughout the whole work.

Unlimited thanks to **all members of my family**, especially my beloved **parents** and my **husband, Omar Ahmed**, for their patience and everlasting support they provided during my research work.

والحمد لله رب العالمين.....

Shaymaa Gamal

Besides the work presented in this thesis, the candidate successfully passed the Master's general and special postgraduate courses in Pharmaceutical Chemistry in the academic year 2017/2018 with the following grades;

1) Scientific Writing and Research Ethics	A–
2) Instrumental Analysis	A
3) Bioinformatics	B+
4) Biostatistics	B+
5) Comprehensive Organic Chemistry	B+
6) Computer Aided Drug Design	A–
7) Methods of Drug Screening	A
8) Structure Elucidation of Chemical Entities	A–
9) Pharmaceutical Chemistry	A
10) Stereochemistry	A–

Table of Contents

TABLE OF CONTENTS	I
LIST OF ABBREVIATIONS.....	V
LIST OF FIGURES.....	X
LIST OF TABLES	XII
ABSTRACT.....	1
1. Introduction.....	6
1.1. Overview about bacteria and infectious diseases.....	6
1.1.1. Anatomy of bacteria.....	6
1.1.1.1. Bacterial cell surface	6
1.1.1.2. Bacterial cell envelope	7
1.1.1.3. Nucleoid region	8
1.1.1.4. Ribosomes.....	9
1.1.2. Infections prevalence.....	9
1.2. Antibacterial agents and their mechanisms of action	10
1.2.1. Antibiotic discovery.....	10
1.2.2. Classes of Antibacterial agents	12
1.3. Bacterial resistance to antibiotics	16
1.3.1. Types of bacterial resistance to antibiotics	16
1.3.1.1. Inherent resistance	16
1.3.1.2. Acquired resistance.....	16
1.3.1.2.1. Vertical gene transfer.....	17
1.3.1.2.2. Horizontal gene transfer.....	17
1.3.2. Mechanisms of bacterial resistance to antibiotics	17
1.3.2.1. Enzymatic inactivation	17
1.3.2.2. Porin modification.....	18
1.3.2.3. Efflux pumps	18

Table of Contents

1.3.2.4. Drugs targets alteration	19
1.4. Antibacterial activity of halogenated thiazolidinones and halogenated thiazolidinone hybrids.....	20
1.4.1. Halogenated thiazolidinones.....	20
1.4.2. Halogenated bis-thiazolidinones	23
1.4.3. Halogenated thiazolidinone hybrids	24
1.4.3.1. Thiazolidinone-sulphonamide hybrids	24
1.4.3.2. Thiazolidinone-6-membered ring hybrids	25
1.4.3.2.1. Thiazolidinone-pyridine/ quinolone hybrids	25
1.4.3.2.2. Thiazolidinone-piperidine hybrids	26
1.4.3.2.3. Thiazolidinone-coumarin hybrids	27
1.4.3.3. Thiazolidinone-5-membered ring hybrids	27
1.4.3.3.1. Thiazolidinone-thiadiazole hybrids	28
1.4.3.3.2. Thiazolidinone-triazole hybrids.....	29
1.4.3.3.3. Thiazolidinone-thiazole/ benzothiazole hybrids	29
1.4.3.3.4. Thiazolidinone-pyrazole hybrids.....	31
1.4.3.3.5. Thiazolidinone-benzimidazole hybrids.....	33
1.4.3.3.6. Thiazolidinone-furan/ thiophene hybrids	33
1.5. Bacterial targets of 4-thiazolidinones.....	34
1.5.1. Cell wall biosynthesis inhibition	34
1.5.1.1. MurB enzyme inhibition	34
1.5.1.2. dTDP-rhamnose biosynthesis inhibition	34
1.5.2. DNA inhibition	35
1.5.2.1. Thiazolidinones as minor groove binders.....	35
1.5.2.2. Thiazolidinones as DNA gyrase and topoisomerase IV inhibitors	36
1.5.3. Protein biosynthesis inhibition	37
1.5.3.1. Aminoacyl-tRNA synthetases inhibition.....	37
1.5.3.2. Cysteine synthase inhibition	37
1.5.4. Bacterial virulence factors inhibition.....	38
1.5.4.1. Urease enzyme.....	38

Table of Contents

1.5.4.2. Secretion systems.....	39
1.5.4.3. Histidine kinase	40
1.5.4.4. Biofilm.....	41
1.6. Synthesis of 4-thiazolidinones	44
1.6.1. Synthesis of 2-substituted thiazolidin-4-ones.....	44
1.6.2. Synthesis of 2,3-disubstituted thiazolidin-4-ones	45
1.6.2.1. Using thioglycolic acid.....	45
1.6.2.1.1. Two-pot three component reaction	45
1.6.2.1.2. One-pot three component reaction	45
1.6.2.2. Using α-halo-acetic acid/ ester	46
1.6.2.2.1. Two-pot three component reaction	46
1.6.2.2.2. One-pot three component reaction	46
1.6.2.3. Substitution at N3 of thiazolidinone ring.....	46
1.6.3. Synthesis of 2,5-disubstituted thiazolidin-4-ones	47
1.6.3.1. Starting from thiourea/ thiosemicarbazide	47
1.6.3.2. Reactions at C5 of thiazolidinones.....	49
1.6.4. Synthesis of 2,3,5-trisubstituted thiazolidin-4-ones.....	50
2. Rationale and design.....	51
2.1. Design of new halogenated 1,3-thiazolidin-4-ones with potential antibacterial activity.....	51
2.2. Synthetic schemes for synthesis of the designed target compounds	54
2.2.1. Scheme 1: Synthesis of compounds 3a-d, 4a-d, 5c-18c and 5d-20d...55	
2.2.2. Scheme 2: Synthesis of compounds 23a-c, 24a-c and 25c-34c	56
3. Results and discussion.....	57
4.1. Chemistry	57
4.1.1. Scheme 1.....	57
4.1.2. Scheme 2.....	63
4.1.3. Radiostability.....	67
4.2. Biological evaluation.....	68
4.2.1. Initial screening of thiazolidinones against bacteria	68

Table of Contents

4.2.2. Effect of the outer membrane and efflux pump on the antibacterial activity of compounds 4a, 4b and 4c against Gram-negative bacterial pathogens	72
4.2.3. Evaluation of the antibacterial activity of compound 16d against a panel of <i>S. aureus</i> clinical isolates.....	74
4.2.4. Investigation of the spectrum of activity of compound 16d against other clinically important Gram-positive bacteria	75
4.2.5. Evaluation of compounds on <i>S. aureus</i> virulence	76
4.2.5.1. Anti-alpha-hemolysin activity	77
4.2.5.2. Anti-biofilm activity.....	79
4.2.6. Cytotoxicity Evaluation	80
4. Conclusion	83
5. Experimental	85
6.1. Chemistry	85
6.1.1. General	85
6.1.2. Irradiation.....	86
6.1.3. Synthesis	86
6.2. Biological assays	134
6.2.1. Bacterial strains and reagents	134
6.2.2. Determination of minimum inhibitory concentration (MIC) against clinically-important Gram-positive and Gram-negative bacteria	134
6.2.3. Anti-virulence evaluation.....	135
6.2.3.1. Anti-hemolysin assessment.....	135
6.2.3.2. MRSA biofilm eradication assessment.....	136
6.2.4. Cytotoxicity	136
6.2.4.1. In vitro cytotoxicity analysis against L929 cells	136
6.2.4.2. In vitro cytotoxicity analysis against Caco-2 cells	137
6. References	138
الملخص العربي.....	أ

List of Abbreviations

AARS(s)	Aminoacyl-tRNA synthetase(s)
Abs	Absorbance
ADAM10	A disintegrin and metalloproteinase-10
DMEM	Dulbecco's modified Eagle's medium
AMR	Antimicrobial resistance
APS	Ammonium persulfate
ATP	Adenosine triphosphate
<i>B. cereus</i>	<i>Bacillus cereus</i>
BHIS	Brain heart infusion supplemented
<i>B. megaterium</i>	<i>Bacillus megaterium</i>
<i>B. subtilis</i>	<i>Bacillus subtilis</i>
Caco-2	Continuous line of heterogeneous human epithelial colorectal adenocarcinoma
CAMHB	Cation adjusted Mueller-Hinton broth
CC₅₀	50% Cytotoxic concentration
CDC	Centers for Disease Control
CFU	Colony forming unit
CLSI	Clinical and Laboratory Standards Institute
CysK1	O-acetylserine sulfhydrylase-A in <i>Mycobacterium tuberculosis</i>
COL	Colistin
DBU	1,8-Diazobicyclo[5.4.0]undec-7-ene

List of Abbreviations

DHFR	Dihydrofolate reductase
DHPS	Dihydropteroate synthase
DIPEA	Diisopropylethylamine
DME	Dimethoxyethane
DMF-DMA	<i>N,N</i> -Dimethylformamide dimethylacetal
DNA	Deoxyribonucleic acid
dTDP	Deoxythymidine diphosphate
<i>E. cloacae</i>	<i>Enterobacter cloacae</i>
<i>E. coli</i>	<i>Escherichia coli</i>
EDG(s)	Electron donating group(s)
<i>E. faecalis</i>	<i>Enterococcus faecalis</i>
Em	Emission
EPS	Extracellular polymeric substance
ESI	Electrospray ionization
EWG(s)	Electron withdrawing group(s)
FBS	Fetal bovine serum FBS
FDA	Food and drug administration
GLASS	Global Antimicrobial Resistance Surveillance System
H	Hour(s)
HC₅₀	50% Hazardous concentration
HGT	Horizontal gene transfer
HK(s)	Histidine kinase(s)
Hla	Alpha-hemolysin